FDA Flags Lower Efficacy For Merck's Keytruda, Roche's Tecentriq In Frontline Bladder Cancer Trials

 
• By Emily Hayes
  
Render illustration of Clinical Trial title on medical documents

More from Immuno-oncology

More from Anticancer